Implanon (Etonogestrel)

Etonogestrel, the hormone in Implanon, binds to progesterone receptors and suppresses the hypothalamic‑pituitary‑ovarian axis. This blocks the luteinizing hormone surge needed for ovulation, thickens cervical mucus, and alters the endometrium, creating conditions that prevent fertilisation and implantation.

Implanon is supplied as a single 68 mg rod that is inserted subdermally by a trained healthcare professional. The prescriber determines suitability and timing; no additional dosing regimen is required after placement.

Implanon is contraindicated in pregnancy and is classified as pregnancy category X. Women who become pregnant while using the implant should have it removed promptly. Breastfeeding is not an absolute contraindication, but clinicians should discuss potential effects on milk production and infant exposure.

To order Implanon, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Compared with daily oral contraceptives, Implanon offers a ‘set‑and‑forget’ approach with no need for daily adherence, and it provides up to three years of protection. Unlike intra‑uterine devices, it does not require uterine placement. Its efficacy is comparable to other progestin implants such as Nexplanon, but the choice depends on patient preference, anatomy and clinical considerations.

Implanon should be stored at ambient temperature below 25 °C, in its original sealed packaging, protected from moisture and direct sunlight. The device must be handled only by qualified personnel trained in subdermal implant insertion and removal to maintain sterility and ensure correct placement.

Implanon is inserted subdermally in the inner side of the upper arm by a qualified healthcare professional. The procedure involves creating a small pocket under the skin, placing the 68 mg rod, and closing the site with a sterile dressing. Removal is performed similarly when the implant reaches the end of its approved duration or if early discontinuation is required.

Serious but rare risks include infection at the insertion site, migration or extrusion of the implant, severe allergic reactions, deep‑vein thrombosis or pulmonary embolism, and ovarian cyst formation. Any signs of persistent abdominal pain, severe swelling, fever, or unusual bleeding should prompt immediate medical evaluation.

Implanon is contraindicated in women who are pregnant, have a known or suspected breast cancer, have active liver disease, have a history of thromboembolic disorders, or have unexplained vaginal bleeding. It should also be avoided in individuals with hypersensitivity to etonogestrel or any component of the implant.